Metachromatic leukodystrophy: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 22: Line 22:


==Classification==
==Classification==
There is no established system for the classification of [disease name].
Based on the age of onset, Metachromatic Leukodystrophy is classified into three types.


OR
Types:  
 
[Disease name] may be classified according to [classification method] into [number] subtypes/groups: [group1], [group2], [group3], and [group4].
 
OR
 
[Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3].
[Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3].
 
OR
 
Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
 
OR


If the staging system involves specific and characteristic findings and features:
- late infantile onset (before 30 months)
According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].


OR
- juvenile onset ( 2.5 years to 16 years)


The staging of [malignancy name] is based on the [staging system].
- adult onset


OR
There is no established system for the staging of [malignancy name].


==Pathophysiology==
==Pathophysiology==
The exact pathogenesis of [disease name] is not fully understood.
Metachromatic leukodystrophy is caused by deficiency of Arylsulfatase A (ASA), an autosomal recessive disorder.
 
OR
 
It is thought that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3].
 
OR
 
[Pathogen name] is usually transmitted via the [transmission route] route to the human host.
 
OR
 
Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell.
 
OR
 
 
[Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells].
 
OR
 
The progression to [disease name] usually involves the [molecular pathway].
 
OR
 
The pathophysiology of [disease/malignancy] depends on the histological subtype.


==Causes==
==Causes==
Line 406: Line 364:
====Clinical Trials====
====Clinical Trials====
Enzyme Replacement Therapy
Enzyme Replacement Therapy
*Phase II clinical trials are underway in Europe by a Danish company, [http://www.zymenex.com Zymenex], using Metazym, ''(updated August 2007)''
*Phase II clinical trials are underway in Europe by a Danish company, [http://www.zymenex.com Zymenex], using Metazym, ''(updated August 2007)''
*[http://www.shire.com/shire/Pipeline/projects.jsp Shire Human Genetics] is proposing an enzyme replacement therapy
*[http://www.shire.com/shire/Pipeline/projects.jsp Shire Human Genetics] is proposing an enzyme replacement therapy
   
   
==See also==
==See also==
*[http://www.evanoskyfoundation.org The Evanosky Foundation]
*[http://www.evanoskyfoundation.org The Evanosky Foundation]
*[http://www.MLDfoundation.org The MLD Foundation]
*[http://www.MLDfoundation.org The MLD Foundation]
Line 415: Line 375:
*[[The Stennis Foundation]]
*[[The Stennis Foundation]]


== External links ==
==External links==
 
*Large portions of this article are courtesy of the public domain text available at the [[National Institute of Neurological Disorders and Stroke]] [http://ninds.nih.gov/disorders/metachromatic_leukodystrophy/metachromatic_leukodystrophy.htm]
*Large portions of this article are courtesy of the public domain text available at the [[National Institute of Neurological Disorders and Stroke]] [http://ninds.nih.gov/disorders/metachromatic_leukodystrophy/metachromatic_leukodystrophy.htm]
*Further information regarding MLD, treatments, genetics, and current research projects, can be found at:
*Further information regarding MLD, treatments, genetics, and current research projects, can be found at:
**[http://www.MLDfoundation.org The MLD Foundation]
**[http://www.MLDfoundation.org The MLD Foundation]
**[http://www.stennisfoundation.org. The Stennis Foundation]
**[http://www.stennisfoundation.org. The Stennis Foundation]
**[http://www.evanoskyfoundation.org/1267/3071.html The Evanosky Foundation]
**[http://www.evanoskyfoundation.org/1267/3071.html The Evanosky Foundation]


*[http://www.emedicine.com/ped/topic2893.htm eMedicine article] about MLD by Theodore Moore, MD.
*[http://www.emedicine.com/ped/topic2893.htm eMedicine article] about MLD by Theodore Moore, MD.
* {{GeneTests|mld}}
*{{GeneTests|mld}}
 





Revision as of 16:01, 4 October 2021

WikiDoc Resources for Metachromatic leukodystrophy

Articles

Most recent articles on Metachromatic leukodystrophy

Most cited articles on Metachromatic leukodystrophy

Review articles on Metachromatic leukodystrophy

Articles on Metachromatic leukodystrophy in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Metachromatic leukodystrophy

Images of Metachromatic leukodystrophy

Photos of Metachromatic leukodystrophy

Podcasts & MP3s on Metachromatic leukodystrophy

Videos on Metachromatic leukodystrophy

Evidence Based Medicine

Cochrane Collaboration on Metachromatic leukodystrophy

Bandolier on Metachromatic leukodystrophy

TRIP on Metachromatic leukodystrophy

Clinical Trials

Ongoing Trials on Metachromatic leukodystrophy at Clinical Trials.gov

Trial results on Metachromatic leukodystrophy

Clinical Trials on Metachromatic leukodystrophy at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Metachromatic leukodystrophy

NICE Guidance on Metachromatic leukodystrophy

NHS PRODIGY Guidance

FDA on Metachromatic leukodystrophy

CDC on Metachromatic leukodystrophy

Books

Books on Metachromatic leukodystrophy

News

Metachromatic leukodystrophy in the news

Be alerted to news on Metachromatic leukodystrophy

News trends on Metachromatic leukodystrophy

Commentary

Blogs on Metachromatic leukodystrophy

Definitions

Definitions of Metachromatic leukodystrophy

Patient Resources / Community

Patient resources on Metachromatic leukodystrophy

Discussion groups on Metachromatic leukodystrophy

Patient Handouts on Metachromatic leukodystrophy

Directions to Hospitals Treating Metachromatic leukodystrophy

Risk calculators and risk factors for Metachromatic leukodystrophy

Healthcare Provider Resources

Symptoms of Metachromatic leukodystrophy

Causes & Risk Factors for Metachromatic leukodystrophy

Diagnostic studies for Metachromatic leukodystrophy

Treatment of Metachromatic leukodystrophy

Continuing Medical Education (CME)

CME Programs on Metachromatic leukodystrophy

International

Metachromatic leukodystrophy en Espanol

Metachromatic leukodystrophy en Francais

Business

Metachromatic leukodystrophy in the Marketplace

Patents on Metachromatic leukodystrophy

Experimental / Informatics

List of terms related to Metachromatic leukodystrophy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chiranjeevi Sainatham, M.B.B.S[2]

Synonyms and keywords: Arylsulfatase A deficiency

Overview

Metachromatic leukodystrophy is the most common form of a family of genetic diseases known as the leukodystrophies, diseases which affect the growth and/or development of myelin, the fatty covering which acts as an insulator around nerve fibres throughout the central and peripherial nervous systems .

Historical Perspective

[Disease name] was first discovered by [name of scientist], a [nationality + occupation], in [year]/during/following [event].

The association between [important risk factor/cause] and [disease name] was made in/during [year/event].

In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name].

In [year], [gene] mutations were first implicated in the pathogenesis of [disease name].

There have been several outbreaks of [disease name], including -----.

In [year], [diagnostic test/therapy] was developed by [scientist] to treat/diagnose [disease name].

Classification

Based on the age of onset, Metachromatic Leukodystrophy is classified into three types.

Types:

- late infantile onset (before 30 months)

- juvenile onset ( 2.5 years to 16 years)

- adult onset


Pathophysiology

Metachromatic leukodystrophy is caused by deficiency of Arylsulfatase A (ASA), an autosomal recessive disorder.

Causes

Disease name] may be caused by [cause1], [cause2], or [cause3].

OR

Common causes of [disease] include [cause1], [cause2], and [cause3].

OR

The most common cause of [disease name] is [cause 1]. Less common causes of [disease name] include [cause 2], [cause 3], and [cause 4].

OR

The cause of [disease name] has not been identified. To review risk factors for the development of [disease name], click here.

Differentiating Metachromatic leukodystrophy from other Diseases

[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].

OR

[Disease name] must be differentiated from [[differential dx1], [differential dx2], and [differential dx3].

Epidemiology and Demographics

The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.

OR

In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.

OR

In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate of [number range]%.


Patients of all age groups may develop [disease name].

OR

The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.

OR

[Disease name] commonly affects individuals younger than/older than [number of years] years of age.

OR

[Chronic disease name] is usually first diagnosed among [age group].

OR

[Acute disease name] commonly affects [age group].


There is no racial predilection to [disease name].

OR

[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].


[Disease name] affects men and women equally.

OR

[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.


The majority of [disease name] cases are reported in [geographical region].

OR

[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

Risk Factors

There are no established risk factors for [disease name].

OR

The most potent risk factor in the development of [disease name] is [risk factor 1]. Other risk factors include [risk factor 2], [risk factor 3], and [risk factor 4].

OR

Common risk factors in the development of [disease name] include [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

OR

Common risk factors in the development of [disease name] may be occupational, environmental, genetic, and viral.

Screening

There is insufficient evidence to recommend routine screening for [disease/malignancy].

OR

According to the [guideline name], screening for [disease name] is not recommended.

OR

According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].

Natural History, Complications, and Prognosis

If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].

OR

Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].

OR

Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.

Diagnosis

Diagnostic Study of Choice

The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].

OR

The diagnosis of [disease name] is based on the [criteria name] criteria, which include [criterion 1], [criterion 2], and [criterion 3].

OR

The diagnosis of [disease name] is based on the [definition name] definition, which includes [criterion 1], [criterion 2], and [criterion 3].

OR

There are no established criteria for the diagnosis of [disease name].

History and Symptoms

The majority of patients with [disease name] are asymptomatic.

OR

The hallmark of [disease name] is [finding]. A positive history of [finding 1] and [finding 2] is suggestive of [disease name]. The most common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3]. Common symptoms of [disease] include [symptom 1], [symptom 2], and [symptom 3]. Less common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3].

Physical Examination

Patients with [disease name] usually appear [general appearance]. Physical examination of patients with [disease name] is usually remarkable for [finding 1], [finding 2], and [finding 3].

OR

Common physical examination findings of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

The presence of [finding(s)] on physical examination is diagnostic of [disease name].

OR

The presence of [finding(s)] on physical examination is highly suggestive of [disease name].

Laboratory Findings

An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].

OR

Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

OR

[Test] is usually normal among patients with [disease name].

OR

Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].

OR

There are no diagnostic laboratory findings associated with [disease name].

Electrocardiogram

There are no ECG findings associated with [disease name].

OR

An ECG may be helpful in the diagnosis of [disease name]. Findings on an ECG suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

X-ray

There are no x-ray findings associated with [disease name].

OR

An x-ray may be helpful in the diagnosis of [disease name]. Findings on an x-ray suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no x-ray findings associated with [disease name]. However, an x-ray may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

Echocardiography or Ultrasound

There are no echocardiography/ultrasound findings associated with [disease name].

OR

Echocardiography/ultrasound may be helpful in the diagnosis of [disease name]. Findings on an echocardiography/ultrasound suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no echocardiography/ultrasound findings associated with [disease name]. However, an echocardiography/ultrasound may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

CT scan

There are no CT scan findings associated with [disease name].

OR

[Location] CT scan may be helpful in the diagnosis of [disease name]. Findings on CT scan suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no CT scan findings associated with [disease name]. However, a CT scan may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

MRI

There are no MRI findings associated with [disease name].

OR

[Location] MRI may be helpful in the diagnosis of [disease name]. Findings on MRI suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no MRI findings associated with [disease name]. However, a MRI may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

Other Imaging Findings

There are no other imaging findings associated with [disease name].

OR

[Imaging modality] may be helpful in the diagnosis of [disease name]. Findings on an [imaging modality] suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

There are no other diagnostic studies associated with [disease name].

OR

[Diagnostic study] may be helpful in the diagnosis of [disease name]. Findings suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

Other diagnostic studies for [disease name] include [diagnostic study 1], which demonstrates [finding 1], [finding 2], and [finding 3], and [diagnostic study 2], which demonstrates [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

There is no treatment for [disease name]; the mainstay of therapy is supportive care.

OR

Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].

OR

The majority of cases of [disease name] are self-limited and require only supportive care.

OR

[Disease name] is a medical emergency and requires prompt treatment.

OR

The mainstay of treatment for [disease name] is [therapy].

OR   The optimal therapy for [malignancy name] depends on the stage at diagnosis.

OR

[Therapy] is recommended among all patients who develop [disease name].

OR

Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].

OR

Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].

OR

Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].

OR

Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Surgery

Surgical intervention is not recommended for the management of [disease name].

OR

Surgery is not the first-line treatment option for patients with [disease name]. Surgery is usually reserved for patients with either [indication 1], [indication 2], and [indication 3]

OR

The mainstay of treatment for [disease name] is medical therapy. Surgery is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].

OR

The feasibility of surgery depends on the stage of [malignancy] at diagnosis.

OR

Surgery is the mainstay of treatment for [disease or malignancy].

Primary Prevention

There are no established measures for the primary prevention of [disease name].

OR

There are no available vaccines against [disease name].

OR

Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

OR

[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].

Secondary Prevention

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].


Clinical Trials

Enzyme Replacement Therapy

  • Phase II clinical trials are underway in Europe by a Danish company, Zymenex, using Metazym, (updated August 2007)
  • Shire Human Genetics is proposing an enzyme replacement therapy

See also

External links


References

Template:Metabolic pathology fi:Metakromaattinen leukodystrofia


Template:WikiDoc Sources